Business Description
MoonLake Immunotherapeutics is a Swiss biotech company working to bring new treatments to patients suffering from inflammatory skin and joint conditions. Its primary focus is Sonelokimab, a next-generation molecule designed to block key proteins that drive inflammation, targeting conditions such as psoriasis, psoriatic arthritis, and related disorders. Founded in 2021 and based in Zug, Switzerland, the company is currently running clinical trials to advance this therapy toward approval.
